Why the study?
Does CYP2C19*17 carrier status affect platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement?
Does CYP2C19*17 carrier status affect platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement?
The CYP2C19*17 allelic variant identifies patients at an increased risk of bleeding and enhanced pharmacodynamic response when treated with clopidogrel after coronary stenting.
May warrant bleeding caution with clopidogrel in CYP2C19*17 carriers; hypothesis-generating for genotype-guided therapy post-stenting.
CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Sibbing et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: